A pilot clinical trial of a recombinant ricin vaccine in normal humans

Ellen S. Vitetta, Joan E. Smallshaw, Elaine Coleman, Hasan Jafri, Callie Foster, Robert Munford, John Schindler

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Ricin, a highly potent toxin produced by castor beans, is classified by the Centers for Disease Control and Prevention as a level B biothreat because it is easily produced, readily available, and highly stable. There have been >750 cases of documented ricin intoxication in humans. There is no approved vaccine for ricin. Ricin contains a lectin-binding B chain and a ribotoxic A chain (RTA). In addition to its ribotoxic site, we have identified a separate site on RTA that is responsible for inducing vascular leak syndrome (VLS) in humans. We have generated a recombinant RTA with two amino acid substitutions that disrupt its ribotoxic site (Y80A) and its VLS-inducing site (V76M). This mutant recombinant RTA (named RiVax) was expressed and produced in Escherichia coli and purified. When RiVax was injected i.m. into mice it protected them against a ricin challenge of 10 LD50s. Preclinical studies in both mice and rabbits demonstrated that RiVax was safe. Based on these results, we have now conducted a pilot clinical trial in humans under an investigational new drug application submitted to the Food and Drug Administration. In this study, three groups of five normal volunteers were injected three times at monthly intervals with 10, 33, or 100 μg of RiVax. The vaccine was safe and elicited ricin-neutralizing Abs in one of five individuals in the low-dose group, four of five in the intermediate-dose group, and five of five in the high-dose group. These results justify further development of the vaccine.

Original languageEnglish (US)
Pages (from-to)2268-2273
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume103
Issue number7
DOIs
StatePublished - Feb 14 2006

Fingerprint

Ricin
Synthetic Vaccines
Clinical Trials
Vaccines
Blood Vessels
Investigational New Drug Application
Castor Bean
Amino Acid Substitution
United States Food and Drug Administration
Centers for Disease Control and Prevention (U.S.)
Healthy Volunteers
Escherichia coli
Rabbits
RiVax

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

A pilot clinical trial of a recombinant ricin vaccine in normal humans. / Vitetta, Ellen S.; Smallshaw, Joan E.; Coleman, Elaine; Jafri, Hasan; Foster, Callie; Munford, Robert; Schindler, John.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 7, 14.02.2006, p. 2268-2273.

Research output: Contribution to journalArticle

Vitetta, Ellen S. ; Smallshaw, Joan E. ; Coleman, Elaine ; Jafri, Hasan ; Foster, Callie ; Munford, Robert ; Schindler, John. / A pilot clinical trial of a recombinant ricin vaccine in normal humans. In: Proceedings of the National Academy of Sciences of the United States of America. 2006 ; Vol. 103, No. 7. pp. 2268-2273.
@article{f9736397df3344ba8665a26a29768a29,
title = "A pilot clinical trial of a recombinant ricin vaccine in normal humans",
abstract = "Ricin, a highly potent toxin produced by castor beans, is classified by the Centers for Disease Control and Prevention as a level B biothreat because it is easily produced, readily available, and highly stable. There have been >750 cases of documented ricin intoxication in humans. There is no approved vaccine for ricin. Ricin contains a lectin-binding B chain and a ribotoxic A chain (RTA). In addition to its ribotoxic site, we have identified a separate site on RTA that is responsible for inducing vascular leak syndrome (VLS) in humans. We have generated a recombinant RTA with two amino acid substitutions that disrupt its ribotoxic site (Y80A) and its VLS-inducing site (V76M). This mutant recombinant RTA (named RiVax) was expressed and produced in Escherichia coli and purified. When RiVax was injected i.m. into mice it protected them against a ricin challenge of 10 LD50s. Preclinical studies in both mice and rabbits demonstrated that RiVax was safe. Based on these results, we have now conducted a pilot clinical trial in humans under an investigational new drug application submitted to the Food and Drug Administration. In this study, three groups of five normal volunteers were injected three times at monthly intervals with 10, 33, or 100 μg of RiVax. The vaccine was safe and elicited ricin-neutralizing Abs in one of five individuals in the low-dose group, four of five in the intermediate-dose group, and five of five in the high-dose group. These results justify further development of the vaccine.",
author = "Vitetta, {Ellen S.} and Smallshaw, {Joan E.} and Elaine Coleman and Hasan Jafri and Callie Foster and Robert Munford and John Schindler",
year = "2006",
month = "2",
day = "14",
doi = "10.1073/pnas.0510893103",
language = "English (US)",
volume = "103",
pages = "2268--2273",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "7",

}

TY - JOUR

T1 - A pilot clinical trial of a recombinant ricin vaccine in normal humans

AU - Vitetta, Ellen S.

AU - Smallshaw, Joan E.

AU - Coleman, Elaine

AU - Jafri, Hasan

AU - Foster, Callie

AU - Munford, Robert

AU - Schindler, John

PY - 2006/2/14

Y1 - 2006/2/14

N2 - Ricin, a highly potent toxin produced by castor beans, is classified by the Centers for Disease Control and Prevention as a level B biothreat because it is easily produced, readily available, and highly stable. There have been >750 cases of documented ricin intoxication in humans. There is no approved vaccine for ricin. Ricin contains a lectin-binding B chain and a ribotoxic A chain (RTA). In addition to its ribotoxic site, we have identified a separate site on RTA that is responsible for inducing vascular leak syndrome (VLS) in humans. We have generated a recombinant RTA with two amino acid substitutions that disrupt its ribotoxic site (Y80A) and its VLS-inducing site (V76M). This mutant recombinant RTA (named RiVax) was expressed and produced in Escherichia coli and purified. When RiVax was injected i.m. into mice it protected them against a ricin challenge of 10 LD50s. Preclinical studies in both mice and rabbits demonstrated that RiVax was safe. Based on these results, we have now conducted a pilot clinical trial in humans under an investigational new drug application submitted to the Food and Drug Administration. In this study, three groups of five normal volunteers were injected three times at monthly intervals with 10, 33, or 100 μg of RiVax. The vaccine was safe and elicited ricin-neutralizing Abs in one of five individuals in the low-dose group, four of five in the intermediate-dose group, and five of five in the high-dose group. These results justify further development of the vaccine.

AB - Ricin, a highly potent toxin produced by castor beans, is classified by the Centers for Disease Control and Prevention as a level B biothreat because it is easily produced, readily available, and highly stable. There have been >750 cases of documented ricin intoxication in humans. There is no approved vaccine for ricin. Ricin contains a lectin-binding B chain and a ribotoxic A chain (RTA). In addition to its ribotoxic site, we have identified a separate site on RTA that is responsible for inducing vascular leak syndrome (VLS) in humans. We have generated a recombinant RTA with two amino acid substitutions that disrupt its ribotoxic site (Y80A) and its VLS-inducing site (V76M). This mutant recombinant RTA (named RiVax) was expressed and produced in Escherichia coli and purified. When RiVax was injected i.m. into mice it protected them against a ricin challenge of 10 LD50s. Preclinical studies in both mice and rabbits demonstrated that RiVax was safe. Based on these results, we have now conducted a pilot clinical trial in humans under an investigational new drug application submitted to the Food and Drug Administration. In this study, three groups of five normal volunteers were injected three times at monthly intervals with 10, 33, or 100 μg of RiVax. The vaccine was safe and elicited ricin-neutralizing Abs in one of five individuals in the low-dose group, four of five in the intermediate-dose group, and five of five in the high-dose group. These results justify further development of the vaccine.

UR - http://www.scopus.com/inward/record.url?scp=33144473223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33144473223&partnerID=8YFLogxK

U2 - 10.1073/pnas.0510893103

DO - 10.1073/pnas.0510893103

M3 - Article

C2 - 16461456

AN - SCOPUS:33144473223

VL - 103

SP - 2268

EP - 2273

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 7

ER -